Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Sunday, November 1, 2026

Back to today

From X

@AsifSuria 3 clicks

Asif Suria on X

As I was working through the insider transactions filed last week for our Insider Weekends article that we have published every Sunday for the last 16 years, these four buys from last Friday stood out to me: 💻 1. A rare insider purchase by Intel's CEO Lip Bu Tan, where he bought $10 million worth of stock after the recent pullback at an average price of $95.00. $INTC The last purchase before that was by the CFO David Zinsner who bought shares in January at an attractive price of $42.50 per share. Former CEO @PGelsinger did even better with his purchases in 2023 and 2024, the last of which were at an average price of $22.53. He is up 365% on that purchase. Lip Bu Tan previously purchased $2.5 million worth of Intel stock in November 2023 when he was the CEO of Cadence $CDNS and was an Intel board member. 🚗 2. A purchase by the Chief Accounting Officer of Valvoline $VVV at an average price of $33.20. While the size of the purchase was not large at about $50K, you don't frequently see purchases by Chief Accounting Officers. @ChrisPavese mentioned that Valvoline was a top contributor to the Broyhill Asset Management portfolio in Q1 2026. ☕️ 3. A purchase by a director of the coffee chain Dutch Bros $BROS where he picked up 2,000 shares at an average price of $51.56. He also purchased shares in May of this year at a slightly lower price. 🧑‍🎓 4. A purchase by a director of Universal Technical Institute $UTI at an average price of $25.94 after a massive drop in the stock last week. Competitor Lincoln Education Services $LINC was also down sharply and I remember liking the thesis for the business after attending a presentation at an investor conference a couple of years ago. Unfortunately I didn't act and buy stock right away. Lincoln is up over 50% over the last year and is up 365% over the last five years despite this recent pullback.
@orrdavid 3 clicks

David Orr on X

I privately told a few fund managers I respect these investing themes/theses privately: "AI is going to drive far more medical/biotech research in pursuit of age reversal technologies than we had before. In fact, at least a couple of these are reasonably likely to be the most valuable companies on the planet in 10-20 years." and related, "Many of the old medical research companies are dinosaurs, since their tech will not keep up with the new age of AI driven medical research." I told them this at the start of 2025, and for example mentioned they avoid shorting $ARKG type stocks. I could tell they thought I was completely retarded, out of my mind, etc. A couple thoughts: 1. I bet those people don't think the idea is stupid at all today. and 2. Having a thesis that seems insane but is often wrong is *awesome*. It's a heads you win, tails you lose nothing situation. Besides $MEDP long, I didn't really know how to play the idea other than avoiding a bunch of shorts. These are theses I still very much believe today, and still today I don't see people talking about them.

Investor Letters

All letters

TSOH Weekly Roundup (10/30/2026)

Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.

BBW $363M
TSOH Investment Research 1 click

OSS Q3 FY12/26 Earnings Analysis

One Stop Systems grew Q3 continuing-operations revenue 36% to $12.6 million, raised FY2026 revenue guidance to $45 million, and used $11.8…

OSS $129M
Cestrian Capital Research 1 click

Namib Minerals: Research Flash

Namib Minerals’ How Mine mill reached 55,000 tonnes per month, 36% above prior capacity, while a proposed $30 million Ecobank facility…

NAMM $43M
Atrium Research - Equity Research 2 clicks

Bimergen Energy: Research Flash

Bimergen Energy filed for a Texas retail-power license to supply data centers directly and gained eligibility for federal contracts through…

BESS $19M
Atrium Research - Equity Research 3 clicks

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $104M
Triple S Special Situations Investing 4 clicks

Moon River Moly: Research Note

Moon River Moly’s updated Davidson PEA lifts after-tax NPV to $1.24 billion as flotation raises tungsten output 350% and cuts molybdenum…

MRIVF $22M
Atrium Research - Equity Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 70 of 272

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

266 firms

Sectors

Ordered by how often our editor reaches for them.